AXSM (Axsome Therapeutics) Other Operating Expense: $6.4 Mil (TTM As of Mar. 2026)


AXSM Axsome Therapeutics Inc AXSM
52 GF Score
Price $244.31
GF Value $222.97
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics Other Operating Expense?

Axsome Therapeutics AXSM +1.52% 52 Other Operating Expense is $6.4 Mil as of Mar. 2026. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $222.97 (Fairly Valued). The stock has 4 warning signs investors should review.

Axsome Therapeutics's Other Operating Expense for the three months ended in Mar. 2026 was $1.6 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $6.4 Mil.

Axsome Therapeutics's quarterly Other Operating Expense stayed the same from Sep. 2025 ($1.6 Mil) to Dec. 2025 ($1.6 Mil) but then declined from Dec. 2025 ($1.6 Mil) to Mar. 2026 ($1.6 Mil).

Axsome Therapeutics's annual Other Operating Expense increased from Dec. 2023 ($6.4 Mil) to Dec. 2024 ($6.4 Mil) but then declined from Dec. 2024 ($6.4 Mil) to Dec. 2025 ($6.4 Mil).

Axsome Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Axsome Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics Other Operating Expense Chart

Axsome Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 4.14 6.38 6.39 6.38

Axsome Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 1.59 1.61 1.61 1.57
AXSM
52GF Score
Axsome Therapeutics Inc AXSM
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $6.4 Mil mean?
Axsome Therapeutics (AXSM) has a Other Operating Expense of $6.4 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Axsome Therapeutics and its competitors.
Is Axsome Therapeutics' Other Operating Expense too high?
Axsome Therapeutics' current Other Operating Expense is $6.4 Mil. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Other Operating Expense compare to MDGL and IONS?
Axsome Therapeutics' Other Operating Expense of $6.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current Other Operating Expense is $6.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Fairly Valued. The stock's GF Value™ is $222.97, compared to a current price of $244.31 — trading 9.6% above its estimated fair value. The current Other Operating Expense is $6.4 Mil. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current Other Operating Expense is $6.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of $244.31 is trading 9.6% above its estimated GF Value™ of $222.97. GuruFocus considers Axsome Therapeutics to be Fairly Valued.

Key valuation signals for AXSM:

  • Other Operating Expense: $6.4 Mil
  • GF Value™: $222.97 vs. price of $244.31 (9.6% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for AXSM

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$244.31
Price
$222.97
GF Value